February 19, 2016
August 5, 2015
May 28, 2015
April 27, 2015
September 19, 2014
September 18, 2014
August 27, 2014
April 7, 2014
Each year over 80,000 women are diagnosed with gynecologic cancers in the U.S. There exists an unmet need in the gynecologic cancer market for innovative and accurate molecular biomarker testing that will aid the gynecologic oncologist in personalizing each patient's treatment plan. OvaGene, through existing tests and future proprietary tests, is poised to fulfill that need with an exciting pipeline of unique gene-based, genomic, and pharmacogenomics tests.
For more information on our company and available investment opportunities, please contact:
OvariGENE, EndoGENE, CerviGENE, Kay's Array, OvaTOX, OvaSEQ are trademarks of OvaGene Oncology, Inc.
Copyright 2017 © OvaGene Oncology, Inc.. All rights reserved.